Research programme: tumour necrosis factor/interleukin 6 inhibitor - Bone Medical

Drug Profile

Research programme: tumour necrosis factor/interleukin 6 inhibitor - Bone Medical

Alternative Names: BN 006

Latest Information Update: 26 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bone Medical
  • Developer Bone Medical; Institute of Bone & Joint Research; William Harvey Research Institute
  • Class Antirheumatics; Peptides
  • Mechanism of Action Interleukin 6 inhibitors; Macrophage inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Rheumatoid arthritis

Most Recent Events

  • 28 Jan 2013 Pharmacodynamics data from a preclinical study in Rheumatoid arthritis released by Bone Medical
  • 01 Mar 2011 Preclinical development is ongoing
  • 21 Dec 2004 Preclinical trials in Rheumatoid arthritis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top